Publication | July 23, 2026
Impaired fetal brain growth and neurodevelopmental deficits at 2 years: deep phenotyping of maternal–fetal pathophysiology
Get the Resource
Read the PaperSapient enabled deep phenotyping with metabolomics to support to a multi-omics study published in The Lancet Obstetrics, Gynaecology, & Women's Health identifying early-pregnancy metabolic signatures associated with fetal brain early faltering growth and developmental deficits.
Impaired fetal cranial growth is associated with lasting deficits in cognition, motor skills, language, and vision, yet the maternal-fetal pathophysiology underlying these childhood development deficiencies remains poorly understood. Early identification of at-risk pregnancies requires molecular insight into the biological processes that drive abnormal fetal development, beyond what traditional clinical measures alone can provide.
The INTERBIO-21st Study – an initiative aimed at improving the phenotypic characterization of fetal growth restriction/small for gestational age (FGR/SGA) and preterm birth syndromes at molecular, biochemical and clinical levels – has previously defined a fetal phenotype characterized by early faltering growth (EFG) of the cranium, which is associated with impaired growth, vision, and neurodevelopment at age 2 years. Their new study, now published in Lancet Obstetrics, Gynaecology, & Women’s Health, refines this phenotype by identifying disruptions in maternal and fetal metabolic pathways associated with EFG of the fetal cranium and brain.
The study builds upon longitudinal fetal cranial and brain growth measurements collected from 3,598 pregnant women across six countries, followed from early pregnancy through age 2 years. Among five distinct fetal cranial growth phenotypes identified, EFG was associated with the most severe neurodevelopmental outcomes.
To investigate the biological drivers of this high‑risk phenotype, the researchers leveraged Sapient’s mass spectrometry‑based discovery metabolomics method to generate deep, unbiased metabolomic profiles from linked maternal early-pregnancy blood and umbilical cord blood samples, enabling the identification of early metabolic signatures associated with EFG.
The analysis revealed distinct maternal phospholipid signatures associated with the EFG phenotype, alongside corresponding alterations in fetal metabolic and epigenetic regulation. Importantly, EFG was associated with faltering volumetric growth of the fetal brain between 14 and 31 weeks’ gestation, without evidence of a significant genetic association with large effect – indicating that this phenotype is not driven by a single dominant genetic cause but rather reflects the influence of maternal, placental, and metabolic factors during pregnancy. Integration of metabolomics with placental physiology, epigenomics, and genomics demonstrated convergent evidence of disrupted lipid metabolism, placental dysfunction, and impaired fetal brain development, linking early maternal metabolic state to downstream developmental outcomes.
This is the first study to investigate large numbers of mother-infant dyads from early pregnancy to childhood, while at the same time exploring a wide-ranging set of variables and molecular pathways. The findings show how deep phenotyping with metabolomics decipher heterogeneous pregnancy biology, revealing early molecular signals that precede structural growth deficits and childhood neurodevelopmental impairment. The study highlights the value of broad metabolomic profiling as a foundational layer for understanding complex maternal-fetal pathophysiology and identifying early biomarkers of developmental risk.
To learn more, read the full paper and findings.